Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Askling

Showing results (21-30 of 345) with videos related to

Pageof 35
Sort By:
JAMA Internal Medicine|October 5, 2017
Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From SwedenHjalmar Wadström, Thomas Frisell, Johan Askling, et al.
Annals of the Rheumatic Diseases|July 16, 2017
Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risksMarie Holmqvist, Lotta Ljung, Johan Askling
Rheumatology (Oxford, England)|November 17, 2022
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis: replyHelga Westerlind, Alf Kastbom, Johan Askling
Arthritis and Rheumatism|August 14, 2012
Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics RegisterJulia F Simard, Martin Neovius, Johan Askling, et al.
Annals of the Rheumatic Diseases|March 17, 2011
How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop?Martin Neovius, Julia F Simard, Johan Askling, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 23, 2006
Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristicsKarin Ekström Smedby, Eva Baecklund, Johan Askling
Annals of the Rheumatic Diseases|September 24, 2013
Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registriesJakub Zavada, William G Dixon, Johan Askling, et al.
Annals of the Rheumatic Diseases|December 15, 2010
Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in SwedenMartin Neovius, Julia F Simard, Johan Askling, et al.
Arthritis and Rheumatism|March 20, 2013
Reply: To PMID 22886739Julia F Simard, Martin Neovius, Johan Askling
RMD Open|December 5, 2019
Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapiesAnnaCarin Horne, Bénédicte Delcoigne, Karin Palmblad, et al.
Pageof 35

Showing results (21-30 of 345) with videos related to

Sort By:
Pageof 35
JAMA Internal Medicine|October 5, 2017
Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From SwedenHjalmar Wadström, Thomas Frisell, Johan Askling, et al.
Annals of the Rheumatic Diseases|July 16, 2017
Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risksMarie Holmqvist, Lotta Ljung, Johan Askling
Rheumatology (Oxford, England)|November 17, 2022
Comment on: The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis: replyHelga Westerlind, Alf Kastbom, Johan Askling
Arthritis and Rheumatism|August 14, 2012
Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics RegisterJulia F Simard, Martin Neovius, Johan Askling, et al.
Annals of the Rheumatic Diseases|March 17, 2011
How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop?Martin Neovius, Julia F Simard, Johan Askling, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 23, 2006
Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristicsKarin Ekström Smedby, Eva Baecklund, Johan Askling
Annals of the Rheumatic Diseases|September 24, 2013
Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registriesJakub Zavada, William G Dixon, Johan Askling, et al.
Annals of the Rheumatic Diseases|December 15, 2010
Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in SwedenMartin Neovius, Julia F Simard, Johan Askling, et al.
Arthritis and Rheumatism|March 20, 2013
Reply: To PMID 22886739Julia F Simard, Martin Neovius, Johan Askling
RMD Open|December 5, 2019
Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapiesAnnaCarin Horne, Bénédicte Delcoigne, Karin Palmblad, et al.
Pageof 35